奥沙利铂联合吉西他滨治疗晚期胆道系统肿瘤的临床观察

Clinical observation of oxaliplatin plus gemcitabine in the treatment of advanced biliary tract carcinoma

目的观察奥沙利铂联合吉西他滨治疗晚期胆道系统肿瘤的疗效及不良反应。方法收集2008年1月至2011年3月均经影像和病理组织学确诊的晚期胆道系统肿瘤38例,具体用药方案:奥沙利铂85mg/m2静滴2h,d1;吉西他滨835 mg/m2静滴30min,d1、d8,21天为1周期。化疗2个周期评价疗效,并记录不良反应。结果 38例均可评价疗效,获CR 1例,PR 7例,有效率(RR)为21.1%(8/38)。主要不良反应包括骨髓抑制、外周神经毒性及恶心呕吐,均未出现重度不良反应。结论奥沙利铂联合吉西他滨治疗晚期胆道系统肿瘤患者的近期疗效较好,不良反应可以耐受,值得深入研究。

Objective To evaluate the efficacy and toxicity of oxaliplatin plus gemcitabine in the treatment of advanced biliar- y tract carcinoma. Methods Thirty-eight patients with advanced bilial3, tract carcinoma diagnosed by imageology and histopathology were treated with oxaliplatin 85 mg/m2 iv 2h, d1 , gemcitabine 835 mg/m^2 iv 30min, d1 and d8. The regimen was repeated every 21 days and at least two cycles. The evaluation was performed after the chemotherapy for two cycles. Results Thirty-eight patients were evaluable for objective response rate. Complete remission （CR） was observed in 1 case and PR in 7 cases, and the objective response rate was 21. 1% （8/38）. The main side-effects were myelosoppression, neuro-sensory toxicity and nausea/vomiting. There were no any death events during treatment. Conclusion Oxaliplatin plus gemcitabine in the treatment of advanced biliary tract carcinoma is ef- fective and tolerable. It is worth of studying in the future.